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Abstract  
Introduction: Tuberculosis (TB) remains a worldwide public health problem with 8.6 millions of new cases and 1.3 millions of death annually. 
Despite the progress recorded in fighting against this disease in the recent years, Africa is still not on the track to achieve the objective to reduce 
by half the death rate due to this disease by 2015. Methods: A case-control study was conducted on data of patients admitted for tuberculosis 
between 1996 and 2011 in the Diagnostic and Treatment Center of Baleng. Cases were patients who died from any cause during anti tuberculosis 
treatment. Logistic regression model was used to identify factors associated to death. Results: In 4201 patients treated during the study period, 
3245 (77.24%) were included in the study. The mean age was 35.9 (SD 14.2) and male represent 62.2% (CI 60.6- 63.9) of them. At the end of 
the follow up, 2883 patients were successfully treated, 362 died during treatment and 132 (36.5%) deaths occurred during the first two months of 
TB treatment. HIV positive status, Extra-pulmonary TB, sputum smear-negative pulmonary TB and male sex were significant independent risk 
factors of death with adjusted odds ratio of 4.8 (CI 3.2- 7.4); 3.0 (CI 1.6- 5.4) ; 2.7 (CI 1.7- 4.4) and 1.5 (CI 1.0- 2.3) respectively. Conclusion: 
The mortality rate of TB patients undergoing TB treatment remains high. Studies are needed to identify and test efficient interventions of mortality 
reduction among TB patients in resource limiting settings.  
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With 8.7 million new cases and a specific mortality of 1.4 million 
cases of death in 2011, tuberculosis remains a major public health 
problem in the world [1]. In 2012, African region was ranked the 
second region with of the highest TB cases with about 27% of 
worldwide cases [1]. In the same year, the prevalence of TB cases 
and death in Cameroon was estimated at 69 thousands and 14.1 
thousands respectively [2]. The fight against TB remains a 
worldwide challenge. It was reinvigorated in 1991, when a World 
Health Assembly (WHA) resolution recognized TB as a major global 
public health problem [3]. From that time, all actions in TB control 
aimed to reduce by 2015 the TB prevalence and death rates by 50% 
relative to 1990 [4]. In the 18 years since the launch of a new 
international strategy for TB care and control by WHO in the mid-
1990s (the DOTS strategy) and the subsequent global rollout of 
DOTS and its successor (the Stop TB Strategy) [5], major progress 
has been observed. Globally, the TB mortality rate has fallen by 
45% since 1990 (with about 4.66.3 million lives saved). It has also 
been observed that the global TB incidence rate is falling in most 
parts of the world [6]. Despite these progresses, TB remains the 
second leading cause of death from an infectious disease worldwide 
[1]. The TB specific rate deaths is unacceptably high given that 
most of cases are preventable if patients can access health care for 
a diagnosis and if they are adequately treated [1]. According to 
WHO, additional efforts are needed in African Region which is 
currently not on track to achieve the mortality and prevalence 
targets [1]. These efforts should include the identification of the 
determinants of death among patients undergoing anti tuberculosis 
treatment. Factors associated to death among TB patients are 
worldwide documented. They are HIV positive status, immune 
depression, negative pulmonary TB, malnutrition, co-morbidity with 
non-infectious diseases, abusive alcohol and drug used [7]. In 
Cameroon, the literature describes characteristics of patients who 
died during tuberculosis treatment [8]. More information is needed 
to improve the survival of TB patients treated on Cameroonian Anti-
tuberculosis Program. In the process of identifying interventions to 
reduce tuberculosis burden, there is a need to identify factors 
associated to death among TB patients. This study had as objective 
to identify, amongst patients diagnosed with TB between 1996 and 
2011in Baleng TB Diagnostic and Treatment Center (DTC) of West 





Study design  
  
It was retrospective case-control study. Cases were defined as 
patients who died from any cause during anti tuberculosis treatment 
and controls were defined as patients successfully treated. Data 
collection was done on medical records of TB patients who came to 
DTC of Baleng between 1996 and 2011.  
  
Study site  
  
The DTC of Baleng is the largest DTC in the western region of 
Cameroon with more than 20 beds exclusively for tuberculosis 
patients. It is located in a semi urban town belonging in Mifi Health 
District. In DTC of Baleng, patients are treated according to the 
WHO Direct Observed Treatment Strategy (DOTS) [9]. At the end of 
patients' follow up, they are classified into six groups[1]: cured 
(patients who are initially sputum smear-positive and who are 
sputum smear-negative in the last month of treatment and on at 
least one previous occasion); Completed treatment (patients who 
complete treatment but do not meet the criteria for cure or failure); 
Failed (patients who are initially sputum smear-positive and who 
remain sputum smear-positive at month 5 or later); Defaulted 
(patient whose treatment are interrupted for two consecutive 
months or more); Transferred (patients who are transferred through 
another DTC during anti tuberculosis treatment) and Died (patients 
who die from any cause during treatment). The patients who are 
cured or those who completed treatment are grouped into 
successfully treated.  
  
Data management  
  
Data was collected from April to august, 2012 by trained surveyors. 
They focused on patients' socio demographic characteristics, 
previous contact with anti tuberculosis treatment, HIV status, and 
clinical files of tuberculosis and treatment outcome. Epi info 
software version 3.5.3 was used for data entry and data analysis. In 
general analysis, proportions (with 95% Confident Interval: 95% CI) 
and means (with Standard Deviation: SD) were calculated. During 
case-control analysis, patients with unknown mortality status 
(referred and those who were lost to follow up) were excluded. 
Patients with incomplete data regarding exposure to suspected risk 
factors were also excluded. For univariate analysis Chi squared test 
(for qualitative variables) and Student's T-test (for quantitative 
variable) were used. To adjust the estimation of Odds Ratio (OR), 
multivariate logistic regression models were constructed. For the 
final model, significant predictors were selected using forward 
stepwise methods. P-values under 0.05 were considered as 
significant. As data were collected in patient's register, no informed 
consent was necessary. The study was approved by the 
administrative authorities of the Diagnostic and Treatment Center of 





General descriptive of participants  
  
In this study, 362 cases of death and 2883 patients successfully 
treated were included in analysis as presented in Figure 1. The 
mean age at the time of diagnosis was 35.9 (SD 14.2) years old and 
male sex was predominant with 2020 participants (62.2% CI 60.6- 
63.9). Age was further categorized into two groups: patients with 
age less than or equal to 40 years old and those with age above 40 
years old. The number of participants aged more than 40 was 969 
(29.9% CI 28.3-31.5). Among patients included in analysis, 2885 
(90.9- 92.8) were new cases of TB whereas 255 (81% CI 7.2- 9.1) 
had an antecedent of anti-tuberculosis treatment. Clinical forms of 
TB were: Extra-pulmonary Tuberculosis, sputum smear-positive 
pulmonary TB and sputum smear-negative pulmonary TB with 
respective frequencies of 145 (4.5% CI 3.8- 5.3); 2677 (82.4% CI 
78.4- 86.2) and 423 (13.0% CI 8.9- 17.1). Among participants with 
known HIV status (35.1%), 305 (26.9% CI 24.3- 29.6) were 
positive and among them, 77 (25.2% CI 19.9- 30.5) had been 
documented as taking antiretroviral therapy (ART). Death occurred 
for 132 (36.5%) patients before the end of the first two months of 
intensive phase of treatment. Globally, the ratio death/successfully 
treated was 0.13 and his evolution by years is presented in Figure 
2.  
  
Factors associated to death  
  
In univariate analysis, as presented in Table 1, socio demographic-
related risk factor which was significantly associated (p < 0.05) with 
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death was age > 40 years. Clinical-related risk factors which were 
significantly associated with death were Extra-pulmonary localization 
of TB and Sputum smear-negative pulmonary. Male sex and 
antecedent of anti TB treatment were associated to patients' death 
but not significantly with p value of 0.31 and 0.21 respectively. 
Significant independent risk factors for death in multivariable logistic 
regression model were male sex, Sputum smear-negative 
pulmonary TB, extra pulmonary TB and HIV positive status. Details 





This study which aimed to identify factors associated to TB patients' 
death has shown that, male sex, sputum smear-negative pulmonary 
TB, Extra-pulmonary TB and HIV positive status were significant 
independent risk factors for death among TB patients treated in 
DTC of Baleng between 1996 and 2011. During the study, data 
were extracted from TB patients' records which can be a source of 
potential information biases. Despite it, the power of the study was 
good due to the number of participants (2883) and to the number 
of deaths (362). The strongest factor associated to death among 
study population was the positive HIV status. This association has 
been observed in others studies implemented in different settings [ 
7, 10-12]. The synergy action of M. tuberculosis and HIV is well 
known and documented. These two pathogens potentiate one 
another, accelerating the deterioration of immunological functions 
and resulting in premature death if untreated or inadequately 
treated [13]. Taking into account the high burden of these diseases 
and their effects on mortality of co-infected patients, the World 
Health Organization recommend implementation of collaborative 
TB/HIV activities. One of these activities is the provision of 
antiretroviral therapy (ART) to all TB patients with HIV infection [4]. 
The effect of ART on the survival of TB patients is well documented 
[14-16]. Despite this benefit of ART, the implementation of 
collaborative TB/HIV activities on the field remains difficult due to 
several management challenges that compromise programmatic 
implementation in resource-limited settings [17]. In our study for 
example, only 25.2% (77) of patients with HIV positive status were 
on ART. Despite it, ART was protective factor of death in univariate 
analysis. The second factor identified as associated to TB patients' 
death in our study was Extra-pulmonary localization of TB. In fact, 
patients with Extra-pulmonary localization of TB had three times 
more risk to die compared to those with pulmonary TB. Extra-
pulmonary TB as factor associated to death has been documented 
in Barcelona, Spain after a population-based cohort study [12]. On 
the other hand, analysis of European surveillance data has shown 
that Extra-pulmonary TB is protective of death compared to 
pulmonary TB. Explanation which can be given to this is the rarity of 
severe forms of Extra-pulmonary TB in the European population. 
Another explanation can be the fact that during that European 
study, patients with both pulmonary and Extra-pulmonary TB were 
included under pulmonary TB [18]. Nevertheless, at our knowledge, 
evaluation of association between Extra-pulmonary TB and patients' 
death is not yet explored in sub-Saharan African Countries. Further 
study should therefore focus on the exploration of that association. 
The third strongest factor associated to death was sputum smear-
negative disease. That association has been shown by other studies 
elsewhere [7, 10]. This association can be explain by the fact that, 
in setting with high prevalence of HIV, sputum smear-negative is 
the expression of advance immune depression [7, 19]. And thus, 
the deaths in these cases are due to opportunistic diseases related 
to AIDS. In our study, the male sex was also associated to patients' 
death. The same results have been shown by others studies [11, 
18, 20]. However, tuberculosis among women remains a major 
public health issue because it is among the top three killers of 
women worldwide [1]. WHO estimate that, in most low-income 
countries, twice as many men are notified with tuberculosis as 
women due to socioeconomic and cultural factors leading to barriers 
in assessing health by women [21]. Intervention aimed to reduce 






The aim of this study was to identify factors associated to death 
among tuberculosis patients treated under Cameroonian National 
Anti-tuberculosis Program. After the reviewed of TB patients' 
records treated from 1996 to 2011 in a major DTC of Bafoussam, 
West Cameroon, factors associated to patients' death was HIV 
positive status, Extra-pulmonary TB, sputum smear-negative 
pulmonary TB and male sex. These groups at risk have to be closely 
follow-up during anti-tuberculosis treatment to achieve the sixth 
Millennium Development Goals. Moreover, studies are needed to 
identify and test efficient interventions of mortality reduction among 
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Table 1: comparison of death and successfully treated groups according to socio 
demographic and clinical characteristics 
Characteristics 
Frequencies 





treated  (N= 
2883) 
(n, %) 
Male sex 234 (11.6) 1786 (88.4) 1.1 (0.8- 1.4) 0.31 
Age ˃ 40 years 115 (16.0) 814 (84.0) 1.9 (1.5- 2.3) ˂ 0.01 




86 (20.3) 337 (79.7) 2.7 (2.1- 3.6) ˂ 0.01 
Antecedent of anti 
TB treatment 
32 (12.5) 223 (87.5) 1.2 (0.8- 1.7) 0.21 
HIV positive 78 (25,6) 227 (74,4) 4,5 (3,1- 6,6) ˂ 0,01 
Anti-Retroviral 
Treatment 




Table 2: multinomial logistic regression of factors associated to death of 
TB patients treated in DTC of Baleng, 1996- 2011 





Male sex 1.5 1.0- 2.3 0.04 
Age ˃ 40 years 1.3 0.9- 2.1 0.13 
Sputum smear-
negative pulmonary TB 
2.7 1.7- 4.4 ˂0.01 
Extra pulmonary 
tuberculosis 
3.0 1.6- 5.4 ˂0.01 
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Figure 2: Evolution of Ratio death/successfully treated in diagnostic and treatment center of Baleng 
 
 
 
 
 
 
 
 
 
